Table 1. Clinical and pathological characteristics of the proposal cohort.
| Characteristics | ypNr0 (n=61) | ypNr1 (n=92) | ypNr2 (n=70) | ypNr3 (n=42) | Total (n=265) | P* | |
|---|---|---|---|---|---|---|---|
| Age | 0.804 | ||||||
| Median (ranges) | 63 (34–80) | 61 (37–78) | 61 (37–77) | 63 (38–76) | 62 (34–80) | ||
| Gender | 0.832 | ||||||
| Man | 47 (77) | 67 (72.8) | 49 (70) | 30 (71.4) | 193 (72.8) | ||
| Woman | 14 (23) | 25 (27.2) | 21 (30) | 12 (28.6) | 72 (27.2) | ||
| ECOG status | 0.290 | ||||||
| 0 | 26 (42.6) | 36 (39.1) | 19 (27.1) | 21 (50) | 102 (38.5) | ||
| 1 | 27 (44.3) | 45 (48.9) | 43 (32.6) | 17 (40.5) | 132 (49.8) | ||
| 2 | 8 (13.1) | 11 (12) | 8 (11.4) | 4 (9.5) | 31 (11.7) | ||
| Primary tumor location | 0.067 | ||||||
| Upper | 11 (18) | 24 (26.1) | 12 (17.1) | 4 (9.5) | 51 (19.2) | ||
| Middle | 10 (16.4) | 17 (18.5) | 5 (7.1) | 11 (26.2) | 43 (16.2) | ||
| Lower | 36 (59) | 43 (46.7) | 47 (67.1) | 21 (50) | 147 (55.5) | ||
| MRI | 4 (6.6) | 8 (8.7) | 6 (8.6) | 6 (8.6) | 24 (9.1) | ||
| Regimen | 0.002 | ||||||
| FOLFOX | 28 (45.9) | 37 (40.2) | 42 (60) | 22 (52.4) | 129 (48.7) | ||
| XELOX | 3 (4.9) | 17 (18.5) | 12 (17.1) | 11 (26.2) | 43 (16.2) | ||
| SOX | 30 (49.2) | 38 (41.3) | 16 (22.9) | 9 (21.4) | 93 (35.1) | ||
| Preoperative cycles | 0.137 | ||||||
| Median (ranges) | 2 (2–7) | 3 (1–7) | 3 (1–7) | 3 (1–6) | 3 (1–7) | ||
| Gastrectomy | 0.060 | ||||||
| DG | 39 (63.9) | 41 (44.6) | 42 (60) | 20 (53.6) | 142 (53.6) | ||
| TG | 22 (36.1) | 51 (55.4) | 28 (40) | 22 (52.4) | 123 (46.4) | ||
| Combined resection | 0.504 | ||||||
| Yes | 4 (6.6) | 12 (13) | 10 (14.3) | 6 (14.3) | 32 (12.1) | ||
| No | 57 (93.4) | 80 (87) | 60 (85.7) | 36 (85.7) | 233 (87.9) | ||
| Differentiation† | 0.001 | ||||||
| Well | 13 (21.3) | 16 (17.4) | 6 (8.6) | 4 (9.5) | 39 (14.7) | ||
| Poorly | 35 (57.4) | 68 (73.9) | 60 (85.7) | 38 (90.5) | 201 (75.8) | ||
| Gx | 13 (21.3) | 8 (8.7) | 4 (5.7) | 0 | 25 (9.4) | ||
| Retrieved lymph nodes | <0.001 | ||||||
| Median (ranges) | 36 (27–76) | 29 (10–86) | 29.5 (9–67) | 31.5 (11–68) | 32 (9–86) | ||
| ypT stage | <0.001 | ||||||
| ypT0 | 10 (16.4) | 7 (7.6) | 4 (5.7) | 0 | 21 (7.9) | ||
| ypT1 | 14 (23) | 5 (5.4) | 0 | 0 | 19 (7.2) | ||
| ypT2/3 | 10 (16.4) | 17 (18.5) | 6 (8.6) | 5 (11.9) | 38 (14.3) | ||
| ypT4 | 27 (44.3) | 63 (68.5) | 60 (85.7) | 37 (88.1) | 187 (70.6) | ||
| ypTNM stage‡ | <0.001 | ||||||
| ypstage I | 24 (47.1) | 8 (9.4) | 0 | 0 | 32 (13.1) | ||
| ypstage II | 27 (52.9) | 27 (52.9) | 5 (7.6) | 0 | 59 (24.2) | ||
| ypstage III | 0 | 50 (58.8) | 61 (92.4) | 42 (100) | 153 (62.7) | ||
| Postoperative chemotherapy | 0.078 | ||||||
| Yes | 56 (91.8) | 77 (83.7) | 49 (70) | 35 (83.3) | 217 (81.9) | ||
| No | 4 (6.6) | 12 (13) | 17 (24.3) | 6 (14.3) | 39 (14.7) | ||
| Unknown | 1 (1.6) | 3 (3.3) | 4 (5.7) | 1 (2.4) | 9 (3.4) | ||
Values are presented as number (%).
ECOG = Eastern Cooperative Oncology Group; MRI = multiple regions involved; FOLFOX = fluorouracil, leucovorin, and oxaliplatin; XELOX = capecitabine combined with oxaliplatin; SOX = S-1 combined with oxaliplatin; DG = distal gastrectomy;TG = total gastrectomy; ypTNM = yield pathological tumor-node-metastasis.
*P<0.05 was considered statistically significant; †Well differentiation included high-and moderately differentiated patients, and poorly differentiated patients included poor and undifferentiated patients. ‡The 21 patients' ypTNM stage cannot be classified according to the 8th edition of the TNM International Union Against Cancer classification: ypT0N0M0 in 13 patients and ypT0N+M0 in 8 patients.